Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients

Figure 4

Total IgG (a) and anti-EBV IgG levels (b) before DES and at 12 months (M) after transplant (Tx) in 35 and 33 DES patients, respectively, who received DES with IVIg + rituximab followed by a kidney transplant with alemtuzumab induction. The results are expressed as mean and standard deviation. The dotted lines describe 7 and 4 mg/ml total IgG for the normal and severe hypogammaglobulinemia cutoff, respectively, in (a), and anti-EBV IgG index 0.25 for sero(+) cutoff level in (b).

(a) Total IgG

(b) Anti-EBV IgG